ATLANTA – The new ophthalmic division of Sun Pharma intends to enter the marketplace with several new products within the next 12 months and a focus on its relationships with professionals.
Jason Menzo, Sun Ophthalmics vice president of sales and marketing, told Primary Care Optometry News in an interview here at SECO that Sun Ophthalmics’ leadership team comprises eye care industry veterans who intend on cultivating relationships with eye care professionals.
“Between now and the fall, we plan on introducing Sun Ophthalmics to the market and educating the industry on what it stands for,” Menzo said. “Our vision is to re-energize eye care by employing passionate people and hyper-focusing on the professional with concierge level customer care.”
Sun anticipates bringing BromSite, a combination of bromfenac and DuraSite, to market in 2016, and Xelpros, a BAK-free formulation of latanoprost in a multidose bottle with a lipid-based micro-emulsion that needs no refrigeration, to market within the next 12 months, he said. Future products will include DexaSite, a combination of dexamethasone and DuraSite, with AzaSite Plus, a combination of azithromycin, dexamethasone and DuraSite, to follow.
“Our goal is to build a multi-faceted ophthalmic company,” Menzo said. “We will bring to market products that are important.”
He said a priority for Sun Ophthalmics is launching its products at an affordable price to ensure inclusion on formularies. – by Nancy Hemphill, ELS, FAAO
Disclosure: Menzo is employed by Sun Ophthalmics.